Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
October 23, 2020
FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided…
Read More
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect
Dave Fornell, Editor
October 22, 2020
FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography
October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from…
Read More
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Dave Fornell, Editor
October 22, 2020
Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable…
Read More
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
October 22, 2020
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology…
Read More
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
October 18, 2020
No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit…
Read More
The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the safety and effectiveness of the Medtronic  IN.PACT 0.014 drug-coated balloon (DCB) in critical limb ischemia (CLI) subjects with chronic total occlusion (CTO) in the infrapopliteal arteries. The data were presented in the Late-Breaking Clinical Trial Sessions at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF). #TCTconnect #TCT2020
October 18, 2020
Drug-coated Balloon for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia
October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the…
Read More
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020
October 18, 2020
Combined FFR and OCT Imaging Can Improve Accuracy of High-Risk Lesion Identification in Patients With Diabetes
October 18, 2020 – Data from the COMBINE (OCT-FFR) study found that the use of FFR combined with OCT imaging can help…
Read More
Illustration showing how the near-infrared spectroscopy (NIRS) intravascular ultrasound (IVUS), of NIRS-IVUS, intracoronary imaging system can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes. The system can identify unstable, vulnerable plaques. #TCTconnect #TCT2020
October 18, 2020
NIRS-IVUS Imaging Can Help Identify High-Risk Plaques That Can Lead to Adverse Outcomes
October 18, 2020 – New data from the PROSPECT II study shows that near-infrared spectroscopy (NIRS) intravascular…
Read More
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0
October 16, 2020
Shockwave Technology to Sonically Bust Calcified Coronary Lesions Shows Safety and Efficacy in U.S. Pivotal IDE Trial
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary…
Read More
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
October 16, 2020
Conformal Medical CLAAS LAA Occluder Shows Promising Clinical Results at TCT 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage…
Read More
The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020
October 16, 2020
Shorter DAPT With Xience Stent is Noninferior to Standard DAPT
October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet…
Read More
The Abiomed Impella was highlighted in several sessions at the 2020 TCT Connect conference. #TCT #TCT2020 #TCTconnect
October 16, 2020
Restore EF Study Demonstrates Impella Supported High-Risk PCI Improves Left Ventricular Ejection Fraction
October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a…
Read More
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect
October 15, 2020
Keystone Heart TAVR Embolic Protection Device Did Not Demonstrate Superiority 
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart…
Read More
Philip's co-registration technology showing angiography overlaid with iFR in a coronary vessel segment with a system of dots that show regions where the hemodynamic pressure drops occur. This can aid in identifying culprit lesions. #TCT #TCT2020 #TCTconnect
October 15, 2020
DEFINE PCI Study One-year Data Show Potential of Treating Residual Ischemia to Improve Outcomes for Coronary Stenting
October 15, 2020 — The one-year results of the late-breaking DEFINE PCI study showed patients had improved outcomes and…
Read More
GE Healthcare announced U.S. FDA 510k clearance for its Ultra Edition package on Vivid cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently.
October 15, 2020
GE Healthcare Receives FDA Clearance for AI-powered Cardiovascular Ultrasound System
October 13, 2020 — GE Healthcare announced U.S. FDA 510k clearance for its Ultra Edition package on Vivid …
Read More
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020. #TCT #TCT2020 #TCTconnect
October 15, 2020
Acurate neo TAVR Valve Fails to Meet Noninferiority With Medtronic CoreValve Evolut
October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs. Medtronic CoreValve Evolut TAVR…
Read More
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect
October 15, 2020
Transcatheter Closure of Residual ASD After Transcatheter Mitral Valve Repair Was Not Superior to Medical Therapy
October 15, 2020 – The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial…
Read More
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
October 15, 2020
TCT 2020 Late-breaking Study Presentations Announced
October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular…
Read More
Effect of COVID-19 on Cardiology Highlighted in Research at ACC Quality Summit. Research examines telehealth, healthcare disparities, as well as impacts on interventional cardiology, patient-centered care.
October 14, 2020
Effect of COVID-19 on Cardiology Highlighted in Research at ACC Quality Summit
October 14, 2020 — American College of Cardiology (ACC) Quality Summit virtual meeting Oct. 8-9, 2020, featured several…
Read More
Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 
October 14, 2020
ACC and CRF Create the Martin B. Leon Center for Cardiovascular Transformation
October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now